Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Terminated1
Completed1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (50.0%)
N/A2 (50.0%)

Trials by Status

terminated125%
completed125%
withdrawn125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnnot_applicable

Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma

NCT00334984
terminatedphase_2

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00334763
completednot_applicable

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
unknownphase_2

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

NCT00323583

Clinical Trials (4)

Showing 4 of 4 trials
NCT00334984Not Applicable

Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma

Withdrawn
NCT00334763Phase 2

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

Terminated
NCT00118339Not Applicable

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

Completed
NCT00323583Phase 2

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Unknown

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4